Fate Therapeutics (NASDAQ:FATE – Get Free Report) and iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.
Profitability
This table compares Fate Therapeutics and iTeos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fate Therapeutics | -1,325.43% | -45.88% | -33.95% |
| iTeos Therapeutics | N/A | -20.11% | -17.50% |
Valuation & Earnings
This table compares Fate Therapeutics and iTeos Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fate Therapeutics | $13.45 million | 14.48 | -$160.93 million | ($1.65) | -1.04 |
| iTeos Therapeutics | $12.60 million | 21.74 | -$112.64 million | ($3.15) | -2.38 |
Analyst Ratings
This is a breakdown of current ratings and price targets for Fate Therapeutics and iTeos Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fate Therapeutics | 0 | 7 | 3 | 0 | 2.30 |
| iTeos Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
Fate Therapeutics presently has a consensus price target of $6.75, suggesting a potential upside of 294.74%. iTeos Therapeutics has a consensus price target of $22.25, suggesting a potential upside of 196.67%. Given Fate Therapeutics’ higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than iTeos Therapeutics.
Institutional and Insider Ownership
97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are owned by institutional investors. 5.0% of Fate Therapeutics shares are owned by company insiders. Comparatively, 12.5% of iTeos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Fate Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.
Summary
iTeos Therapeutics beats Fate Therapeutics on 8 of the 14 factors compared between the two stocks.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
About iTeos Therapeutics
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
